Selective TBK1/IKKi dual inhibitors with anticancer potency

International Journal of Cancer

Volumn 134, Issue 8, 2014, Pages 1972-1980

  Li, Jijia ^a,b   Huang, Jingjia ^c   Jeong, Ji Hak ^b   Park, Sun Jin ^b   Wei, Rui ^a,b   Peng, Jieying ^a   Luo, Zhiyong ^c   Chen, Yen Ting ^b   Feng, Yangbo ^b   Luo, Jun Li ^b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

cancer; IKKi; TBK1; TBK1 IKKi inhibitor; therapy

Indexed keywords

CANCER; IKKI; TBK1; TBK1/IKKI INHIBITOR; THERAPY;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; FEMALE; HUMANS; I-KAPPA B KINASE; MACROPHAGES; MALE; MICE; MICE, NUDE; MOUTH NEOPLASMS; NEOPLASMS; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; RNA INTERFERENCE; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84893730428     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28507     Document Type: Article

References (33)

1. Rothwarf DM, Karin M,. The NF-kappa B activation pathway: a paradigm in information transfer from membrane to nucleus. Sci STKE 1999;1999:RE1.
2. Karin M, Ben-Neriah Y,. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 2000; 18: 621-63. (Pubitemid 30365393)
3. Greten FR, Karin M,. NF-kB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005; 5: 749-59. (Pubitemid 41400849)
4. Luo JL, Kamata H, Karin M,. IKK/NF-kappaB signaling: balancing life and death-a new approach to cancer therapy. J Clin Invest 2005; 115: 2625-32. (Pubitemid 41434385)
5. Shen RR, Hahn WC,. Emerging roles for the non-canonical IKKs in cancer. Oncogene 2011; 30: 631-41.
6. Clement JF, Meloche S, Servant MJ,. The IKK-related kinases: from innate immunity to oncogenesis. Cell Res 2008; 18: 889-99.
7. Bonnard M, Mirtsos C, Suzuki S, et al. Deficiency of T2K leads to apoptotic liver degeneration and impaired NF-kappaB-dependent gene transcription. EMBO J 2000; 19: 4976-85.
8. Hemmi H, Takeuchi O, Sato S, et al. The roles of two IkappaB kinase-related kinases in lipopolysaccharide and double stranded RNA signaling and viral infection. J Exp Med 2004; 199: 1641-50. (Pubitemid 38821997)
9. Chien Y, Kim S, Bumeister R, et al. RalB GTPase-mediated activation of the IkappaB family kinase TBK1 couples innate immune signaling to tumor cell survival. Cell 2006; 127: 157-70. (Pubitemid 44472624)
10. Boehm JS, Zhao JJ, Yao J, et al. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 2007; 129: 1065-79. (Pubitemid 46891036)
11. Barbie DA, Tamayo P, Boehm JS, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009; 462: 108-12.
12. Bodemann BO, White MA,. Ral GTPases and cancer: linchpin support of the tumorigenic platform. Nat Rev Cancerss 2008; 8: 133-40. (Pubitemid 351187648)
13. Boehm JS, Zhao JJ, Yao J, et al. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 2007; 129: 1065-79. (Pubitemid 46891036)
14. Xie X, Zhang D, Zhao B, et al. IkappaB kinase epsilon and TANK-binding kinase 1 activate AKT by direct phosphorylation. Proc Natl Acad Sci USA 2011; 108: 6474-9.
15. Ou YH, Torres M, Ram R, et al. TBK1 directly engages Akt/PKB survival signaling to support oncogenic transformation. Mol Cell 2011; 41: 458-70.
16. Bamborough P, Christopher JA, Cutler GJ, et al. 5-(1H-Benzimidazol-1-yl)- 3-alkoxy-2-thiophenecarbonitriles as potent, selective, inhibitors of IKK-epsilon kinase. Bioorg Med Chem Lett 2006; 16: 6236-40. (Pubitemid 44712060)
17. Wang T, Block MA, Cowen S, et al. Discovery of azabenzimidazole derivatives as potent, selective inhibitors of TBK1/IKKepsilon kinases. Bioorg Med Chem Lett 2012; 22: 2063-9.
18. Clark K, Plater L, Peggie M, et al. Use of the pharmacological inhibitor BX795 to study the regulation and physiological roles of TBK1 and IkappaB kinase epsilon: a distinct upstream kinase mediates Ser-172 phosphorylation and activation. J Biol Chem 2009; 284: 14136-46.
19. McIver EG, Bryans J, Birchall K, et al. Synthesis and structure-activity relationships of a novel series of pyrimidines as potent inhibitors of TBK1/IKKepsilon kinases. Bioorg Med Chem Lett 2012; 22: 7169-73.
20. Solis M, Romieu-Mourez R, Goubau D, et al. Involvement of TBK1 and IKKepsilon in lipopolysaccharide-induced activation of the interferon response in primary human macrophages. Eur J Immunol 2007; 37: 528-39. (Pubitemid 46915591)
21. Gatot JS, Gioia R, Chau TL, et al. Lipopolysaccharide-mediated interferon regulatory factor activation involves TBK1-IKKepsilon-dependent Lys(63)-linked polyubiquitination and phosphorylation of TANK/I-TRAF. J Biol Chem 2007; 282: 31131-46. (Pubitemid 350044889)
22. Hutti JE, Shen RR, Abbott DW, et al. Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKK epsilon promotes cell transformation. Mol Cell 2009; 34: 461-72.
23. Gulen MF, Bulek K, Xiao H, et al. Inactivation of the enzyme GSK3alpha by the kinase IKKi promotes AKT-mTOR signaling pathway that mediates interleukin-1-induced Th17 cell maintenance. Immunity 2012; 37: 800-12.
24. Guo JP, Coppola D, Cheng JQ,. IKBKE protein activates Akt independent of phosphatidylinositol 3-kinase/PDK1/mTORC2 and the pleckstrin homology domain to sustain malignant transformation. J Biol Chem 2011; 286: 37389-98.
25. Chen J, Somanath PR, Razorenova O, et al. Akt1 regulates pathological angiogenesis, vascular maturation and permeability in vivo. Nat Med 2005; 11: 1188-96. (Pubitemid 43093666)
26. Tenoever BR, Ng SL, Chua MA, et al. Multiple functions of the IKK-related kinase IKKepsilon in interferon-mediated antiviral immunity. Science 2007; 315: 1274-8. (Pubitemid 46364264)
27. Fujita F, Taniguchi Y, Kato T, et al. Identification of NAP1, a regulatory subunit of IkappaB kinase-related kinases that potentiates NF-kappaB signaling. Mol Cell Biol 2003; 23: 7780-93. (Pubitemid 37271475)
28. Buss H, Dorrie A, Schmitz ML, et al. Constitutive and interleukin-1-inducible phosphorylation of p65 NF-{kappa}B at serine 536 is mediated by multiple protein kinases including I{kappa}B kinase (IKK)-{alpha}, IKK{beta}, IKK{epsilon}, TRAF family member-associated (TANK)-binding kinase 1 (TBK1), and an unknown kinase and couples p65 to TATA-binding protein-associated factor II31-mediated interleukin-8 transcription. J Biol Chem 2004; 279: 55633-43. (Pubitemid 40068850)
29. Rokavec M, Wu W, Luo JL,. IL6-mediated suppression of miR-200c directs constitutive activation of inflammatory signaling circuit driving transformation and tumorigenesis. Mol Cell 2012; 45: 777-89.
30. Rokavec M, Luo JL,. The transient and constitutive inflammatory signaling in tumorigenesis. Cell Cycle 2012; 11: 2587-8.
31. Eddy SF, Guo S, Demicco EG, et al. Inducible IkappaB kinase/IkappaB kinase epsilon expression is induced by CK2 and promotes aberrant nuclear factor-kappaB activation in breast cancer cells. Cancer Res 2005; 65: 11375-83. (Pubitemid 41823949)
32. Adli M, Baldwin AS,. IKK-i/IKKepsilon controls constitutive, cancer cell-associated NF-kappaB activity via regulation of Ser-536 p65/RelA phosphorylation. J Biol Chem 2006; 281: 26976-84. (Pubitemid 44401726)
33. Radisavljevic Z,. AKT as locus of cancer angiogenic robustness and fragility. J Cell Physiol 2013; 228: 21-4.